第一医药
(600833)
| 流通市值：30.70亿 | | | 总市值：30.70亿 |
| 流通股本：2.23亿 | | | 总股本：2.23亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 996,596,339.46 | 503,963,782.8 | 1,915,159,154.27 | 1,368,880,300.43 |
| 营业收入 | 996,596,339.46 | 503,963,782.8 | 1,915,159,154.27 | 1,368,880,300.43 |
| 二、营业总成本 | 994,289,666.33 | 497,905,553.68 | 1,908,589,189.92 | 1,367,026,359.88 |
| 营业成本 | 831,770,568.01 | 418,553,990.57 | 1,596,660,714.13 | 1,140,076,016.83 |
| 税金及附加 | 2,658,425.62 | 1,659,098.46 | 5,879,527.54 | 4,125,527.36 |
| 销售费用 | 134,637,834.62 | 66,467,454.03 | 252,304,833.4 | 191,832,654.92 |
| 管理费用 | 29,804,790.93 | 13,323,616.06 | 67,764,721.76 | 41,681,103.09 |
| 财务费用 | -4,581,952.85 | -2,098,605.44 | -14,020,606.91 | -10,688,942.32 |
| 其中:利息费用 | 2,382,139.34 | 1,364,504.46 | 6,049,917.48 | 4,510,224.26 |
| 其中:利息收入 | 7,124,179.51 | 3,545,859.42 | 20,956,663.76 | 17,145,957 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | 379,109.59 | - |
| 加:投资收益 | 8,489,595.84 | 580,197.28 | 12,905,483.23 | 10,739,697.33 |
| 资产处置收益 | 404,944.23 | 29,143.12 | 169,174,142.38 | 140,908,008.63 |
| 资产减值损失(新) | - | - | -4,789,484.62 | - |
| 信用减值损失(新) | 1,396,756.29 | - | 23,300,492.52 | -270,036 |
| 其他收益 | 292,042.29 | 175,681.26 | 532,275.27 | 415,914.24 |
| 四、营业利润 | 12,890,011.78 | 6,843,250.78 | 208,071,982.72 | 153,647,524.75 |
| 加:营业外收入 | 5,568,574.02 | 28,607.12 | 11,268,736.46 | 41,208,224.81 |
| 减:营业外支出 | 715,224.59 | 488,759.54 | 3,069,455.62 | 884,283.12 |
| 五、利润总额 | 17,743,361.21 | 6,383,098.36 | 216,271,263.56 | 193,971,466.44 |
| 减:所得税费用 | 3,421,496.13 | 1,579,619.07 | 52,655,904.6 | 46,613,373.74 |
| 六、净利润 | 14,321,865.08 | 4,803,479.29 | 163,615,358.96 | 147,358,092.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 14,321,865.08 | 4,803,479.29 | 163,615,358.96 | 147,358,092.7 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 14,024,192.23 | 4,739,088.09 | 163,061,272.77 | 147,324,925.33 |
| 少数股东损益 | 297,672.85 | 64,391.2 | 554,086.19 | 33,167.37 |
| 扣除非经常损益后的净利润 | 9,012,019.73 | 4,495,482.77 | 6,874,046.12 | 7,813,112.45 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.02 | 0.73 | 0.66 |
| (二)稀释每股收益 | 0.06 | 0.02 | 0.73 | 0.66 |
| 八、其他综合收益 | 5,004,193.22 | -464,615.21 | -1,354,766.19 | -698,050.74 |
| 归属于母公司股东的其他综合收益 | 5,004,193.22 | -464,615.21 | -1,354,766.19 | -698,050.74 |
| 九、综合收益总额 | 19,326,058.3 | 4,338,864.08 | 162,260,592.77 | 146,660,041.96 |
| 归属于母公司股东的综合收益总额 | 19,028,385.45 | 4,274,472.88 | 161,706,506.58 | 146,626,874.59 |
| 归属于少数股东的综合收益总额 | 297,672.85 | 64,391.2 | 554,086.19 | 33,167.37 |
| 公告日期 | 2025-08-20 | 2025-04-30 | 2025-04-09 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |